ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
Healthcare
$1.10 +12.28%
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
52W Low $1.33High $3.10
Volume 0.88M
Average 0.62M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$50.71M
FY 2025 · Annual
Investing Cash Flow
-$979,742.00
FY 2025 · Annual
Financing Cash Flow
-$1.76M
FY 2025 · Annual
Cash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (60.8M) | (64.2M) | (27.74M) | (27.76M) | (40.52M) |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| Deferred Income Tax | 117K | 96K | (78K) | (197K) | 0 |
| Stock-Based Compensation | 6.22M | 2.87M | 3.11M | 2.54M | 0 |
| Change in Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Other Non-Cash Items | 1.11M | (4.8M) | (5.21M) | (474K) | 3.94M |
| Operating Cash Flow | (26.01M) | (68.51M) | 21.55M | (36.39M) | (50.71M) |
| Capital Expenditures | (484K) | (708K) | (1.37M) | (1.42M) | (979.75K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (17M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 17M | 0 |
| Other Investing Activities | 59K | 6K | 5.65M | (2.66M) | 0 |
| Investing Cash Flow | (425K) | (702K) | 4.28M | (4.07M) | (979.74K) |
| Debt Repayment | 26.84M | (45.05M) | (2.63M) | (1.58M) | (1.91M) |
| Common Stock Issued | 108.48M | 14.12M | 0 | 71.64M | 66.28K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | 34K | 354K | 223K | 75.19K |
| Financing Cash Flow | 136.83M | (30.89M) | (2.28M) | 70.28M | (1.76M) |
| Effect of Forex Changes | 1.29M | 7.35M | 599K | 673K | 14.15M |
| Net Change in Cash | 111.69M | (92.75M) | 24.15M | 30.48M | (39.3M) |
| Free Cash Flow | (26.5M) | (69.22M) | 20.18M | (37.81M) | (51.69M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$40.5M
+ D&A$2.6M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$16.7M
+ Other Non-Cash$3.9M
= Operating Cash Flow-$50.7M
- Capex-$979.7K
= Free Cash Flow-$51.7M
Analysis
FY2025 free cash flow is -$51.7M. FCF conversion is 127.6% of net income. Operating cash flow was -$50.7M, with capex of -$979.7K. The largest bridge item is Working Capital at -$16.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K/A | 6-K/A filing | Oct 30, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Sep 23, 2026 |
Does PRQR generate free cash flow?
ProQR Therapeutics N.V. (PRQR) generated -$51.69M of free cash flow in fiscal 2025.
How much operating cash flow does PRQR produce?
Operating cash flow was -$50.71M, before capital expenditures of $979,745.00.
Continue the stock analysis
Jump to another research area for this company.